News coverage about Grifols, (NASDAQ:GRFS) has been trending positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Grifols, earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near future.
A number of equities analysts have issued reports on GRFS shares. J P Morgan Chase & Co raised Grifols, from a “neutral” rating to an “overweight” rating in a research note on Thursday, March 30th. Bank of America Corporation started coverage on Grifols, in a research note on Thursday, April 6th. They set a “buy” rating for the company. HSBC Holdings plc lowered Grifols, from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Zacks Investment Research lowered Grifols, from a “buy” rating to a “hold” rating in a research note on Friday, May 5th. Finally, BidaskClub lowered Grifols, from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $24.00.
Grifols, (NASDAQ GRFS) opened at 20.88 on Monday. The firm’s 50-day moving average price is $21.42 and its 200-day moving average price is $18.78. Grifols, has a 52 week low of $14.27 and a 52 week high of $22.83. The company has a market capitalization of $27.98 billion, a price-to-earnings ratio of 44.57 and a beta of 0.98.
What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.